
Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.
“The field of biomarkers in prostate cancer is exploding exponentially, and it has been for some time now,” Shore says. “The challenge is that most of the biomarkers that are commercially available are not reimbursed and, some might argue, are truly not yet ready for primetime.”





